FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Feb 11, 2026
Viking Therapeutics, Inc. (VKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $359.6 million. As of Sep 30, 2026 it held $959.8 million in cash and investments and $4.0 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-627.20M
-164.2% vs year-ago TTM
Operating cash flow (TTM)
$-462.63M
-106.0% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-5.41
-155.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
115.55M
+2.9% vs prior year
Net cash
$955.77M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1607678
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M |
| Diluted EPS | -$3.19 | -$1.01 | -$0.91 | -$0.90 | — |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
| Stockholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M |
| Cash and investments | $705.7M | $902.6M | $362.1M | $155.5M | $202.1M |
| Total debt | $137,000 | $1.1M | $1.3M | $1.6M | $29,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 28, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 652 Viking Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.